Moderna Inc. (MRNA) beat expectations in Q1 FY2026 on revenue of $389.0M versus the $236.4M estimate (+263.6% YoY) and EPS of $-3.40. The next Moderna Inc. (MRNA) earnings date is Jul 31, 2026. Below is the full Moderna Inc. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Moderna Inc. (MRNA) Earnings Analysis — key stats
Next earnings date
Jul 31, 2026
Latest reported quarter
Q1 FY2026
Earnings verdict
Beat
EPS beat rate
7 of last 8 (quarters above estimate)
Avg next-day move
±9.4% (over the last 8 reports)
Post-earnings direction
Up 4 / Down 4 (of the last 8 reports)
Implied move (next report)
±23.7% (options-derived · into Jul 31, 2026)
Revenue
$389.0M (vs $236.4M est · +64.6% surprise · +263.6% YoY)
EPS
$-3.40 (vs $-4.45 est · +23.6% surprise · +34.9% YoY)
Share price
$79.76 (+10.0%)
Market cap
$31.6B
Moderna Inc. (MRNA) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q2 2026
$389.0M vs $236.4M est
$-3.40 vs $-4.45 est
+23.6%
+3.0%
Beat
Q1 2026
$678.0M vs $635.2M est
$-2.11 vs $-2.54 est
+16.9%
+9.5%
Beat
Q4 2025
$1.0B vs $920.9M est
$-0.51 vs $-1.87 est
+72.7%
+4.2%
Beat
Q3 2025
$142.0M vs $893.3M est
$-2.13 vs $-2.99 est
+28.8%
-6.5%
Mixed
Q2 2025
$107.0M vs $116.7M est
$-2.52 vs $-2.92 est
+13.7%
-3.3%
Mixed
Q1 2025
$956.0M vs $942.8M est
$-2.50 vs $-2.68 est
+6.7%
+12.0%
Mixed
Q4 2024
$1.9B vs $1.3B est
$0.03 vs $-1.91 est
+101.6%
-9.6%
Beat
Q3 2024
$241.0M vs $128.4M est
$-3.33 vs $-3.35 est
+0.6%
-27.4%
Mixed
What you'll find
Next Moderna Inc. (MRNA) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Moderna Inc. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Moderna Inc. (MRNA)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Moderna Inc.'s next earnings date?
Moderna Inc.'s (MRNA) next scheduled earnings date is Jul 31, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Moderna Inc. (MRNA) beat or miss earnings?
In Q1 FY2026, Moderna Inc. (MRNA) posted beat results — revenue of $389.0M versus the $236.4M estimate (+64.6% surprise) and EPS of $-3.40 versus $-4.45 expected (+23.6% surprise). Magnisto decodes every Moderna Inc. (MRNA) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does Moderna Inc. beat earnings estimates?
Over its last 8 reported quarters, Moderna Inc. (MRNA) beat Wall Street EPS estimates 7 times, most recently a beat result in Q2 2026. Magnisto tracks every Moderna Inc. (MRNA) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does Moderna Inc. stock move after earnings?
Over its last 8 quarterly reports, Moderna Inc. (MRNA) moved an average of ±9.4% the day after earnings — ranging from -27.4% (Q3 2024) to +12.0% (Q1 2025). The stock rose after 4 of those 8 reports and fell after 4. Heading into its next report on Jul 31, 2026, options-implied volatility is pricing in a move of roughly ±23.7% (derived). Magnisto tracks the realized post-earnings move for every Moderna Inc. (MRNA) quarter alongside the beat/miss verdict — past moves don't predict the next one.
What is the forecast for Moderna Inc. (MRNA) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Moderna Inc. (MRNA), anchored to the current $79.76 share price, so you can weigh the bull, base and bear cases for Moderna Inc. side by side.
Is Moderna Inc. (MRNA) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Moderna Inc. fits your own thesis and risk profile. This is research, not investment advice.